Lonza Group Ltd (0QNO.IL)
| Previous close | 402.20 |
| Open | 401.50 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 396.40 - 404.10 |
| 52-week range | 396.40 - 767.40 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division
Lonza Group AG / Key word(s): PersonnelLonza Appoints Daniel Palmacci as President of the Cell & Gene Division 12.09.2022 / 07:00 CET/CEST Daniel Palmacci joins Lonza as President of the Cell & Gene Division and member of the Executive Committee Daniel will commence his tenure with Lonza Group on 1 November 2022, bringing deep industry knowledge, international experience and expertise in leading cross-functional teams Daniel takes over leadership of Cell & Gene from Jean-Christophe Hyvert, who w
- EQS Group
Lonza and Touchlight collaborate on end-to-end mRNA offering
Lonza Group AG / Key word(s): PartnershipLonza and Touchlight collaborate on end-to-end mRNA offering 06.09.2022 / 07:00 CET/CEST Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNATM) Touchlight provides synthetic DNA through a cell-free enzymatic process, with advantages of speed, quality, capacity, and scalability Customers can gain access to Touchlight’s dbDNA as an integral par
- EQS Group
Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
Lonza Group AG / Key word(s): Half Year Results22-Jul-2022 / 07:01 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR In H1 2022, Lonza delivers CHF 3 billion sales and 16.8%1 CER sales growth CHF 987 million CORE EBITDA resulted in a margin of 33.1% H1 2022 CAPEX reached 28.2% of sales as Lonza continues to execute planned investments Group Outlook 2022 confirmed at low
